What is Endoret®(prgf®) technology?
Endoret®(prgf®) (Plasma Rich in Growth Factors) Technology: It is an advanced autologous Platelet-Rich Plasma system. It is based on the activation of the patient's own platelets for the stimulation and acceleration of tissue healing and regeneration.
What advantages does Endoret®(prgf®) offer?
- 100% biocompatible, versatile and safe.
- It is the market's first 100% autologous technology.
- Control over its activation and use.
- A simple protocol: just one centrifugation.
- A fast protocol: just 8 minutes of centrifugation and 20 minutes of preparation..
- Its clinical efficiency in the stimulation of tissue healing and regeneration has been described in a large number of international articles.
- It does not contain leucocytes, avoiding their proinflammatory activity.
- Powerful bacteriostatic properties.
- Excellent therapeutic potential in different clinical applications.
What sets Endoret®(prgf®) Technology apart from other technologies in the market?
- It is a pioneer (Patent no EP1066838) in the development of specific protocols for tissue regeneration.
- It is backed by a large number of international scientific studies and publications.
- It is a versatile system that makes it possible to create different formulations that adapt to the characteristics of each application.
- Excellent efficiency of the volume of blood extracted with this system.
Intended for international use only. Indications for use of products and/or therapies contained herein may not be cleared /approved for use by the following Health international agencies: US Food & Drug Administration, Health Canada or Japanese Health Ministry. To access the specific information of your market, use the country selector located on the top menu of this page.